role biomarkers demonstrating efficacy clinical trials alzheimer especially early stage ones new guidelines major step forward fast tracking drugs disease need comparable tests preferably blood tests help diagnose alzheimer evaluate treatments aid making clinical trials rigorous affordable efficient accelerate drug development improve clinical care providing access accurate diagnoses new initiative called diagnostics accelerator auspices alzheimer drug discovery foundation aims develop novel biomarkers blood accessible fluids tissue markers specifically tied alzheimer forms dementia allow predict accurately treatment prevention strategies work risk populations cancer heart disease diseases aging article originally published title new strategy alzheimer scientific american 320 2 7 february 2019